Wells Fargo lowered the firm’s price target on Tenet Healthcare (THC) to $229 from $252 and keeps an Overweight rating on the shares. For managed care organizations, the firm is most constructive on Medicare Advantage with uncertainty high for Medicaid/Exchanges. Wells sees a more difficult backdrop for hospitals in 2026 as post-COVID tailwinds wane and legislative risks near. Distributor debate remains revisions vs. multiples.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $247 from $232 at Morgan Stanley
- Hospital stocks lower after Republicans propose Medicare funding cut
- Tenet Healthcare price target raised to $257 from $238 at Guggenheim
- Tenet Healthcare Board Member Resigns, Board Size Reduced
- Tenet Healthcare price target raised to $240 from $229 at Barclays